Literature DB >> 20646947

Spondyloarthropathies: an independent cardiovascular risk factor?

Sylvain Mathieu1, Pascal Motreff, Martin Soubrier.   

Abstract

An increase in cardiovascular mortality and morbidity has been convincingly documented in rheumatoid arthritis. Data on spondyloarthropathies are more limited. Here, we discuss published studies indicating that patients with spondyloarthropathies are at increased risk for cardiovascular disease. The excess risk is probably multifactorial, being related both to chronic systemic inflammation and to high prevalences of conventional cardiovascular risk factors. Cardiovascular risk management in patients with spondyloarthropathies requires optimal control of disease activity combined with interventions targeting conventional cardiovascular risk factors.
Copyright © 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20646947     DOI: 10.1016/j.jbspin.2010.05.001

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  19 in total

1.  Mortality in patients with ankylosing spondylitis in Argentina.

Authors:  Emilio Andres Buschiazzo; Emilce Edith Schneeberger; Fernando Andres Sommerfleck; Cesar Ledesma; Gustavo Citera
Journal:  Clin Rheumatol       Date:  2016-07-04       Impact factor: 2.980

2.  Thrombin generation in ankylosing spondylitis.

Authors:  Clément Prati; Evelyne Racadot; Jean-Pierre Cedoz; Daniel Wendling
Journal:  Clin Rheumatol       Date:  2010-08-17       Impact factor: 2.980

Review 3.  Sex and Cardiovascular Involvement in Inflammatory Joint Diseases.

Authors:  Santos Castañeda; Carlos González-Juanatey; Miguel A González-Gay
Journal:  Clin Rev Allergy Immunol       Date:  2019-06       Impact factor: 8.667

4.  Ischemic heart disease and ankylosing spondylitis-assessing the role of inflammation.

Authors:  Michal Vinker Shuster; Omer Gendelman; Shmuel Tiosano; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Clin Rheumatol       Date:  2018-02-22       Impact factor: 2.980

Review 5.  Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis.

Authors:  Fernanda Genre; Raquel López-Mejías; José A Miranda-Filloy; Begoña Ubilla; Beatriz Carnero-López; Ricardo Blanco; Trinitario Pina; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Biomed Res Int       Date:  2014-03-18       Impact factor: 3.411

6.  Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis--a population-based longitudinal follow-up study.

Authors:  Ya-Ping Huang; Yen-Ho Wang; Shin-Liang Pan
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

7.  Cardiac conduction system abnormalities in ankylosing spondylitis: a cross-sectional study.

Authors:  Helena Forsblad-d'Elia; Hanna Wallberg; Eva Klingberg; Hans Carlsten; Lennart Bergfeldt
Journal:  BMC Musculoskelet Disord       Date:  2013-08-12       Impact factor: 2.362

8.  Comparison of venous thromboembolism after total hip arthroplasty between ankylosing spondylitis and osteoarthritis.

Authors:  Dongquan Shi; Xingquan Xu; Kai Song; Zhihong Xu; Jin Dai; Dongyang Chen; Qing Jiang
Journal:  Biomed Res Int       Date:  2014-06-04       Impact factor: 3.411

Review 9.  Endothelial dysfunction in chronic inflammatory diseases.

Authors:  Curtis M Steyers; Francis J Miller
Journal:  Int J Mol Sci       Date:  2014-06-25       Impact factor: 5.923

10.  Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect.

Authors:  Fernanda Genre; Raquel López-Mejías; Javier Rueda-Gotor; José A Miranda-Filloy; Begoña Ubilla; Beatriz Carnero-López; Natalia Palmou-Fontana; Inés Gómez-Acebo; Ricardo Blanco; Trinitario Pina; Rodrigo Ochoa; Carlos González-Juanatey; Javier Llorca; Miguel A González-Gay
Journal:  Mediators Inflamm       Date:  2014-05-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.